Effect of CYP3A5 gene polymorphism on tacrolimus valley concentration in early postoperative renal transplant recipients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029257

Enrollment

Unknown

Registered

2020-01-19

Start date

2020-01-16

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal transplant

Interventions

case series:tacrolimus

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) first kidney transplantation; (2)The renal transplant recipients were given a tacrolimus-based triple immunosuppressive regimen (tacrolimus + mycophenol + glucocorticoid).

Exclusion criteria

Exclusion criteria: (1)multi-organ transplantation; (2)Pregnant and nursing women; (3)liver function serious injury or serious gastrointestinal diseases, gastrointestinal resection, malabsorption syndrome; (4)Had participated in the clinical study of other drugs 1 month before the study; (5)patients with hypersensitivity or intolerance to macrolides, macaulate, glucocorticoids.

Design outcomes

Primary

Measure	Time frame
genotype;boby weight;	—

Secondary

Measure	Time frame
systolic blood pressure;diastolic blood pressure;alanine transaminase;aspartate aminotransferase;fasting blood glucose;hemoglobin;creatinine;estimated glomerular filtration rate;	—

Countries

China

Contacts

Public ContactLi Yan

The First Hospital Affiliated with Shandong First Medical University

Li_xyan@126.com+86 13791126823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026